Faron Pharmaceuticals Oy Exercise of options (4747N)
01 June 2022 - 4:00PM
UK Regulatory
TIDMFARN
RNS Number : 4747N
Faron Pharmaceuticals Oy
01 June 2022
Faron Pharmaceuticals Ltd.
("Faron")
Exercise of options
Issue of equity
Company announcement, June 1, 2022 at 07:00 am BST / 9:00 am
EEST
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM:
FARN, First North: FARON), a clinical stage biopharmaceutical
company focused on building the future of immunotherapy by
harnessing the power of the immune system to tackle cancer and
inflammation, announces that it has received notifications from
option holders to exercise 2015D options over 25,000 shares in the
Company at an exercise price of EUR 1.09 (approx. GBP 0.93) per
share under the Company's 2015 Option Plan ("New Ordinary Shares").
The terms and conditions of the 2015 Option Plan are available on
the Company's website at
https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf
.
Applications have been made to the London Stock Exchange and
Nasdaq Helsinki to admit the New Ordinary Shares to trading on AIM
and Nasdaq First North Growth Market, respectively. Admission of
the New Ordinary Shares is expected to occur on or around June 7,
2022 following issue and registration of the New Ordinary Shares on
or around June 6, 2022 ("Registration"). The New Ordinary Shares
will rank pari passu with existing ordinary shares.
Faron's enlarged issued number of shares immediately following
Registration will be 53,257,032 ordinary shares with voting rights
attached. The Company has no shares in treasury; therefore upon,
and subject to, Registration, the total number of voting rights in
Faron will be 53,257,032. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine whether they are required to notify an interest in, or a
change to their interest in, the issued shares and votes of the
Company.
For more information please contact:
Investor Contact
Faron Pharmaceuticals
Julia Balanova
VP, Investor Relations
julia.balanova@faron.com
investor.relations@faron.com
Phone: +1 (917) 306-6096
Media Contact
Faron Pharmaceuticals
Eric Van Zanten
VP, Communications
eric.vanzanten@faron.com
Phone: +1 (610) 529-6219
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
faron@consilium-comms.com
Phone: +44 (0)20 3709 5700
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs caused by dysfunction of
our immune system. The Company currently has a pipeline based on
the receptors involved in regulation of immune response in
oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanized antibody, is its investigative
precision immunotherapy with the potential to provide permanent
immune stimulation for difficult-to-treat cancers through targeting
myeloid function. Currently in Phase I/II clinical development as a
potential therapy for patients with solid tumors and hematologic
malignancies, bexmarilimab has potential as a single-agent therapy
or in combination with other standard treatments including immune
checkpoint molecules. Traumakine is an investigational intravenous
(IV) interferon beta-1a therapy for the treatment of acute
respiratory distress syndrome (ARDS) and other ischemic or
hyperinflammatory conditions. Traumakine is currently being
evaluated by the 59th Medical Wing of the US Air Force and the US
Department of Defense for the prevention of multiple organ
dysfunction syndrome (MODS) after ischemia-reperfusion injury
caused by a major trauma. Faron is based in Turku, Finland. Further
information is available at www.faron.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEDFLFXLELXBBX
(END) Dow Jones Newswires
June 01, 2022 02:00 ET (06:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024